Next Article in Journal
Real-Time Analysis of Oxygen Gradient in Oocyte Respiration Using a High-Density Microelectrode Array
Next Article in Special Issue
Distinguishing Amyloid β-Protein in a Mouse Model of Alzheimer’s Disease by Label-Free Vibrational Imaging
Previous Article in Journal
An Electrochemical Evaluation of Novel Ferrocene Derivatives for Glutamate and Liver Biomarker Biosensing
Previous Article in Special Issue
The Spectroscopic Properties and Microscopic Imaging of Thulium-Doped Upconversion Nanoparticles Excited at Different NIR-II Light
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease

Center for Biomedical Photonics, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen 518060, China
*
Author to whom correspondence should be addressed.
Biosensors 2021, 11(8), 255; https://doi.org/10.3390/bios11080255
Submission received: 23 June 2021 / Revised: 21 July 2021 / Accepted: 26 July 2021 / Published: 29 July 2021

Abstract

:
Alzheimer’s disease (AD) is a multifactorial, irreversible, and incurable neurodegenerative disease. The main pathological feature of AD is the deposition of misfolded β-amyloid protein (Aβ) plaques in the brain. The abnormal accumulation of Aβ plaques leads to the loss of some neuron functions, further causing the neuron entanglement and the corresponding functional damage, which has a great impact on memory and cognitive functions. Hence, studying the accumulation mechanism of Aβ in the brain and its effect on other tissues is of great significance for the early diagnosis of AD. The current clinical studies of Aβ accumulation mainly rely on medical imaging techniques, which have some deficiencies in sensitivity and specificity. Optical imaging has recently become a research hotspot in the medical field and clinical applications, manifesting noninvasiveness, high sensitivity, absence of ionizing radiation, high contrast, and spatial resolution. Moreover, it is now emerging as a promising tool for the diagnosis and study of Aβ buildup. This review focuses on the application of the optical imaging technique for the determination of Aβ plaques in AD research. In addition, recent advances and key operational applications are discussed.

1. Introduction

Alzheimer’s disease (AD) is an irreversible neurodegenerative disease caused by a variety of factors [1]. The disease is still currently incurable, being the number three cause of mortality worldwide after cardiovascular diseases and cancer [2,3,4]. According to a recent World Alzheimer’s report [5], a new case of AD appears every 3 s. Moreover, 50 million cases of AD currently exist worldwide and are expected to reach 152 million in 2050. However, the disease still cannot be identified in the early stages and cannot be effectively cured, and its exact mechanism remains unclear. Many patients have missed the precious opportunity for early treatment due to not being timely diagnosed because the incubation period of AD can be as long as 10 to 20 years. Thus, emphasizing that the survival rate and the quality of life of patients can be greatly improved is important if the disease can be detected at early stages and given an effective treatment. Therefore, the development of methods for early AD diagnosis is of the highest significance and value for the treatment and prevention of AD.
A large number of senile plaques composed of Aβ in the brain of patients with AD has been shown [6]. These plaques produce a neurotoxic effect, causing structural destruction and neuronal network function and make the brain microenvironment of patients with AD significantly different from that of the normal brain [7,8,9]. The Aβ theory has been recognized as the most classical theory in AD pathogenesis. A large number of studies have confirmed the central position of the Aβ theory in AD pathogenesis [10]. The mainstream theory believes that the production and deposition of Aβ is the root and fuse of AD, and the development of anti-Aβ therapeutics remains to be a rational approach to AD treatment [11]. Therefore, the study of the deposited Aβ is conducive to further understand AD pathogenesis and the development of diagnostic methods. In vivo Aβ detection would be a feasible way to realize the early AD diagnosis. However, a lack of high sensitivity detection methods still exists.
The imaging techniques for the clinical AD diagnosis currently mainly include computed tomography (CT) [12], magnetic resonance imaging (MRI) [13,14,15,16,17,18], functional magnetic resonance imaging (fMRI) [19], positron emission tomography (PET) [20], single-photon emission computed tomography (SPECT) [21,22], magnetic resonance spectroscopy (MRS) [23], and so on. In addition, MRI, PET, and SPECT have shown effectiveness in Aβ imaging of the AD brain. However, the imaging of brain pathological changes under the microscope is limited by the long acquisition time and restricted spatial resolution. In addition, their high cost and use of radioactive isotopes or ionizing radiation make them difficult to be used as an early screening tool for everyone. Most importantly, subjective factors in diagnosis appear as the imaging interpretation depends on the clinical experience of the physician. Thus, alternative technologies that are relatively cheap and easy to apply have recently attracted increasing attention.
Compared with clinical imaging modalities, optical imaging possesses many advantages (e.g., noninvasiveness, high sensitivity, low cost, high imaging speed, and the ability to carry out three-dimensional imaging with high spatial and temporal resolution), allowing for the detection of biological processes at the cellular or molecular level [24,25,26]. The application of fluorescence microscopy allows for the use of fluorescent probes to label Aβ in histological studies [27,28]. However, traditional microscopy can be prone to axial and lateral interference, which results in images becoming blurry. The emergence of confocal laser scanning microscopy (CLSM) provides a solution to the axial and lateral interference of fluorescence signal and also allows for optical sectioning, which can be used for three-dimensional imaging of thicker samples [29,30]. However, the use of fluorescent probes may cause certain toxic effects to living organisms, restraining the in vivo imaging. In recent years, researchers have devoted not only to the development of many new near-infrared fluorescent probes [31,32] but also label-free imaging [33,34]. Nonlinear optical imaging is widely used in the study of dynamic biological and physicochemical processes in vitro and in vivo due to the advantages of label-free, chemically specific, and high-speed imaging [35,36,37,38,39,40,41]. In recent years, nonlinear optical imaging technology has also been employed in the AD research field. In particular, it was applied to the detection of Aβ and tau aggregates, neurofibrillary tangles, and cerebral amyloid angiopathy; assessment of dendritic spines and accumulation of senile plaques; evaluation of the development of TPPP/p25 aggregates in patients with AD [42,43,44]. This review briefly introduces optical imaging methods and focuses on their application to Aβ plaque imaging (Figure 1).

2. Conventional Fluorescence Microscopy Imaging

Fluorescence microscopy (FM) is a very powerful tool in biomedicine, which takes ultraviolet as the light source, the wavelength is short, and the resolution is higher than that of ordinary microscopy. The FM principle scheme is shown in Figure 2. FM uses special dichromatic mirrors that reflected shorter wavelengths of light and transmitted longer wavelengths of light. Thus, only the longer wavelength red light from the object can be seen and not the scattered violet light. In addition, FM is commonly used to study the absorption and transportation of intracellular substances, and the distribution and location of chemical substances. Moreover, it has been widely used in the biomedicine field due to its strong detection ability, minor stimulation to the organism, and multiple staining in vivo.
When FM is used in the AD diagnosis field, although Aβ protein itself does not have strong endogenous fluorescence, the specific luminescence mechanism of the fluorescent probe can be used to realize the visualization of Aβ protein. Moreover, an exogenous fluorescent probe can be used to label and visualize Aβ proteins. Fluorescent dyes used for protein labeling can fluoresce brightly at very low concentrations and are generally nontoxic to the body, allowing for in vivo studies. In 2011, Karonyo-Hamaoui et al. [45] reported that Aβ plaques can be found earlier in the retina than that in the brain and accumulate as the disease progresses. They used curcumin as a fluorescent label to perform in vivo fluorescence imaging of Aβ plaques in the retina of AD-Tg mice by utilizing a Micron II rodent retinal imaging microscope (a comprehensive ophthalmology research platform developed by Phoenix Research Labs specially designed for small experimental animals’ eyes, as shown in Figure 3). Those plaques were not detected in the non-Tg mice. Furthermore, the effect of MOG45D [46], which has been reported to effectively inhibit Aβ plaque load on retinal plaques was evaluated, and the plaque changes were validated using curcumin as a fluorescent probe. In the 2014 Alzheimer’s Society International Conference, Frost et al. [47] used a novel system of neurovision imaging and a technique called retinal amyloid imaging to detect Aβ in the eye. The patient also had PET imaging of the Aβ in the brain. The results showed that Aβ levels in the retina were closely related to those in the brain and confirmed that the retina was also an area of high plaque deposition. Furthermore, in 2018, Tes et al. [48] tested Cy5 and CRANAD-2 (a compound derived from curcumin) as fluorescent probes for observing the growth of plaques in the retina with a fluorescence imaging system. The result shows that CRANAD-2 is a better fluorescent probe for Aβ imaging. Cy5 can colocate with CRANAD-2, which lays a foundation for fluorescence imaging of labeled Aβ.
In the Aβ imaging of the brain in vitro, Ikonomovic et al. [49] recently used the FM to compare the ability of two fluorescence probes (i.e., flutemetamol and PiB) to bind to plaques. The results showed that the plaque load of flutemetamol and PiB are strongly correlated, and both of them correspond with the Aβ immunohistochemistry.

3. Confocal Laser Scanning Microscopy Imaging

The excitation light, in general, irradiates on the sample to generate fluorescence, and the fluorescence signal is strongest at the focal point of the lens. However, some light scattered by the excitation light will also irradiate other parts of the sample to produce a fluorescence signal on a nonconjugated surface. This will cause fuzzy and faint fluorescence contributions from outside of the focal plane. In addition, a confocal microscope solves the interference of axial and lateral direction of image because the focal point of the objective lens and pinhole point are conjugate points to each other to obtain high resolution (Figure 4). A pinhole is used to block non-focal plane signals to eliminate focus blurring. Confocal microscopy can filter out signals reaching the detector from out of the focal plane because of the pinhole. This allows for collecting signals from focal planes one by one when changing focus and using the collected images to reconstruct the three-dimensional structure of thick samples. Using confocal microscopy, samples can be scanned and imaged to analyze the three-dimensional spatial structure of cells without damage (Figure 5) [50]. This technique allows for the optimum visualization of the brain structures, producing informative images.
In the study of the relationship between Aβ plaques and astrocytes or microglia, Li [51] investigated the variance in the endocytosis, transport, and degradation mechanisms of β-amyloid monomer and oligomer on astrocytes by CLSM, and found that both sAβ42 and oAβ42 could enter astrocytes via macrophage. In a later study, Icke et al. [52] used immunohistochemistry and CLSM to not only collect three-dimensional image datasets from AD mouse models but also automatically detect plaques and their associated microglial responses as well as neuronal damage. Preliminary studies demonstrated that plaque-associated microglia clustering is correlated with plaque size. The data showed that plaque-associated microglia had similar neuroprotective effects on small and large plaques in the early stages of the disease. However, this kind of protection decreased in the late stage. This approach will allow for unbiased quantitative assessment of potential neuroprotective effects in preclinical AD models with Aβ pathology.
Photobiomodulation (PBM) [53] is a developing field of biomedical research. PBM uses low-level/intensity/power laser or monochromatic light to regulate biological functions and has been used to treat AD and other neurodegenerative diseases in recent years. Hannah et al. [54] demonstrated that stimulating the eyes of AD mice with a 40-Hz light-emitting diode flash to induce gamma waves eliminated amyloid deposits. Moreover, Singer et al. [55] have also reached the above conclusion observed through the CLSM. These observations indicate that light induction may cause a systemic effect in the brain, which promoted PBM feasibility in AD treatment. However, further study is still needed to confirm whether it will be therapeutic in human AD.
Alsunusi et al. [56] used the CLSM in the study of the Aβ aggregation mechanism to detect Aβ localization in PC12. In each PC12 construct, the Aβ immunoreactivity response was found to begin in the neurons at 12 h and to initiate plaque deposition, which indicated that the Aβ accumulation increased with time. However, more studies are needed to determine the deposition and AD pathogenesis caused by intraneuronal Aβ aggregation.
In addition to the study of the brain section, the retinal amyloid deposits have also been found by CLSM. Furthermore, Chibhabha et al. [57] found that the staining of the curcumin micelles are colocalized with that of the anti-Aβ42 antibody, and both can excellently stain the plaque region in the hippocampal sections and retina. This study provides a basis for optical imaging of retinal amyloid plaques through the eye in vivo.
However, the spatial resolution of wide-field/confocal FM was limited by the Abbe/Rayleigh limit of light diffraction and could not distinguish structures below 200 nm. Researchers have also recently adopted some new optical imaging methods to improve the image resolution of Aβ plaques. Moreover, Wang et al. [58] synthesized a series of aggregation-induced emission fluorogens to enhance fluorescence intensity. Both PD-NA and PD-NA-TEG fluorescence probes exhibit excellent binding to Aβ plaques, and the imaging resolution can be improved to <100 nm using the super-resolution fluorescence imaging system, allowing for clearer observation of Aβ deposition. Furthermore, Ni et al. [59] developed a novel imaging approach by overlaying signals extracted from small focal points to form high-resolution images. Transcranial amyloid deposition can be imaged across the entire brain of mice with AD at a 20-μm resolution by using this large field of view multi-focus FM in combination with a near-infrared dye. To further improve the resolution of the three-dimensional imaging system, Prof. Hui Gong’s team from Wuhan National Research Center for Optoelectronics used the self-developed fluorescence micro-optical sectioning tomography system to image the whole brain and completed the first high-resolution three-dimensional reconstruction of hypothalamic–neurohypophysial system. Immunostaining showed that the detection rate of Aβ plaques larger than 10 μm in diameter was 97.71% ± 0.18%. A dataset of Aβ plaque distributed throughout the brain of 5XFAD transgenic mice was obtained with an imaging resolution of 0.32 × 0.32 × 2 μm [60]. This approach will contribute to the comprehensive and efficient study of the pathogenesis and efficacy evaluation of AD.

4. Near-Infrared Fluorescence Imaging

Near-infrared fluorescence imaging (NIRF) has been rapidly developed in recent years because of its high sensitivity, noninvasiveness, simple operation, and the ability to avoid the interference of spontaneous fluorescence in biological tissues. NIRF fluorescent imaging mainly includes the development of biocompatible NIR fluorescent dyes and the synthesis of various probes. During conventional fluorescence imaging in the visible range, both excitation and emission are absorbed or scattered by the tissue, resulting in significant attenuation of the detected emission signal. Moreover, the tissue autofluorescence (which is mostly in the visible range) also interferes with the emission signal acquisition. The scattering and absorption of excitation and emission can be effectively reduced and the required lower excitation energy causes less damage to the biological tissue when the wavelength of the probe is located in the near-infrared region (NIR, 650 to 900 nm). The NIRF has become an essential tool for the analysis of biological samples in vitro and in vivo imaging of small animals. Moreover, the use of amyloid-specific excitable fluorescence probes with emission at 600 to 700 nm has the advantage in comparison with conventionally used probes as they are well suited for deep imaging of amyloid plaques in AD mouse brain in vivo [61,62]. Therefore, the use of NIRF probes targeting Aβ plaques in the brain is of great significance for preclinical study, histopathological examination, and construction of AD models [63,64,65]. NIRF fluorescent imaging mainly includes the development of biocompatible NIR fluorescent dyes and the synthesis of various probes. The ideal NIRF fluorescent probe should have the following characteristics: (1) targeting Aβ with high selectivity and high affinity, (2) the emission wavelength is in the near-infrared spectral range, (3) rapid penetration of the blood–brain barrier (BBB) and rapid clearance in the organism, (4) high quantum yield, (5) low affinity with bovine serum albumin (BSA), (6) easy synthesis, and most importantly, (7) binding to Aβ plaques, which should significantly change its fluorescence properties (e.g., fluorescence intensity, fluorescence lifetime, emission wavelength, and quantum yield). In this section, the application of NIR probes in Aβ imaging and some commercial NIR imaging instruments will be described.
Raymond et al. [25,65] compared specific probes for Aβ with emission wavelengths at 630 and 800 nm and showed that the probes with emission wavelengths at 800 nm had a better signal-to-noise ratio and a higher affinity for Aβ, which would improve the current near-infrared amyloid imaging capability and beyond that of AO1987 (with absorption and emission peaks at 650 and 750 nm, which makes it the most efficient probe for Aβ plaque in the brain at that time). Moreover, curcumin is a specific probe for imaging Aβ plaques. However, its application in near-infrared imaging is limited due to its short emission wavelength and limited transmission through the blood–brain barrier. Furthermore, Ran et al. [64] designed a NIRF probe derived from curcumin, CRANAD-2, with emission at 805 nm. The fluorescence intensity was significantly increased by 70 times in the presence of Aβ aggregates compared with the fluorescence intensity observed in phosphate-buffered saline (pH 7.4). In addition, CRANAD-2 was colocalized with standard thioflavin T staining signals in an in vitro brain tissue analysis. In in vivo experiments, the fluorescence intensity of the transgenic group was higher than that of the control group, and the plaques were colocalized with histological staining signals.
Schmidt et al. [66] then developed in 2012 a novel NIRF probe THK-265(Ex = 665 nm, Em = 725 nm, and Kd = 97 nM) to investigate the different stages of Aβ plaques in transgenic mice in vivo by using an Odyssey® Infrared Imaging System (OIIS, LI-COR Biosciences, Lincoln, NE, USA). The results showed that the intensity of the NIRF signal was closely related to plaque load, indicating its practical value in monitoring directly the progression of Aβ aggregation, and opening the possibility of effective presymptom monitoring of Aβ deposition in the aging brain. In addition, Yang et al. [32] recently demonstrated that NIRF ocular imaging (NIRFOI), which was performed on IVIS® Spectrum (PerkinElmer, Hopkinton, MA, USA) could provide higher sensitivity for Aβs than brain NIRF imaging does. By using NIRFOI with a near-infrared probe CRANAD-102 (Ex = 605 nm, and Em = 680 nm), they have observed significant CRANAD-102 expression in APP/PS1 at about 60 min, while WT has not. This high sensitivity is significant for both diagnosis and therapy monitoring.

5. Nonlinear Optical Microscopic Imaging

In linear optics, the electric polarization intensity induced by particles in the medium under the action of the external photoelectric field is proportional to the intensity of the incident photoelectric field, i.e., P = ε _ 0   χ E . However, the electric polarization intensity in nonlinear optics is not proportional to the intensity of the incident of the photoelectric field. That is:
P = ε 0 ( χ ( 1 ) E + χ ( 2 ) E 2 + χ ( 3 ) E 3 + )
where ε 0 is the permittivity of free space and χ ( 1 ) is the linear susceptibility describing the linear optical process. χ ( 2 ) and χ ( 3 ) are the second- and third-order nonlinear optical susceptibilities.
Nonlinear optical microscopy can be categorized into one- and two-beam modalities. The one-beam modality includes multiphoton excited fluorescence (MPEF), second-harmonic generation (SHG), and third-harmonic generation (THG) microscopy. The two-beam modality includes coherent anti-Stokes Raman scattering (CARS), four-wave mixing, stimulated Raman scattering (SRS), and pump probe. Moreover, two-photon excited fluorescence (TPEF) provides a good molecular signal-to-noise ratio for images and has the ability of label-free morphological imaging. The strongest source of SHG is fibrous collagen. In addition, CARS is derived from molecular vibration. Thus, it has chemical selectivity and chemical specificity [42]. Nonlinear optical techniques have been widely used to study biological samples because of their high optical spatial and temporal resolution, the absence of required additional labeling, nondestructive manipulation, and chemical specificity. This part mainly introduces Aβ imaging by several nonlinear optical imaging techniques, including MPEF, SHG, THG, CARS, and SRS [42].

5.1. Multiphoton Excited Fluorescence Microscopy

The most common multiphoton imaging techniques are TPEF and three-photon excited fluorescence (3PEF) imaging. MPEF uses a near-infrared femtosecond laser pulse to replace the traditional ultraviolet light source, which has better imaging depth, lower optical damage, higher spatial resolution and contrast, and less photobleaching compared with the traditional single-photon FM [67,68,69,70]. In addition, MPEF has the advantage of selective imaging, which allows for the study of only the place of interest without being disturbed by the surrounding environment. Multiphoton microscopy has been widely used in biomedical fields in recent years and has shown great application potential in the diagnosis of a variety of diseases due to its advantages.
Previous studies have reported senile plaque imaging using MPEF, which can be considered as an ideal imaging tool for preclinical studies in AD mice models both in vivo and in vitro [71,72,73,74]. However, tissue diffusion limits the maximum depth of imaging of the mouse cerebral cortex with two-photon excitation FM. Either removal of the covered brain tissue or the introduction of an optical probe is required to solve this problem. MPEF has been employed for imaging amyloid plaques and their surrounding structures in the mouse brain in vivo by removing part of the skull or thinning skull together with different fluorescent labels such as ThS or thiazine red or fluorescently labeled anti-amyloid antibodies. Bacskai et al. [75] used the MPEF combined with ThS to directly observe the clearance of plaques in live mouse brains with immunotherapy. Christie et al. [71] used MPEF combined with ThS to observe Aβ plaques in vivo over several months. Chen et al. [76] successfully used a novel near-infrared probe for deep-brain imaging of amyloid plaques in vivo in AD mouse models without interference from a lipofuscin signal.
Based on previous studies, many researchers have focused on the factors affecting the dynamics of amyloid plaque formation and growth in vivo by using MPEF imaging. In 2003, the Alzheimer’s Disease Research Unit of Massachusetts General Hospital [71] reported the average number of plaques in the cortex of ThS-stained Aβ plaques from Tg2576 transgenic mice increased nearly sixfold from 12 to 22 months, while the size distribution of plaque diameters did not change significantly. Moreover, Yan et al. [77] found that the 6-month-old APP/PS1 mice showed more robust plaque growth than the 10-month-old mice, suggesting that plaque growth is more prominent in the early stage of disease and that early disease treatment may be more effective than treatment later in the disease.
Moreover, MPEF is especially useful for observing the relationship between Aβ deposits and microglial, amyloid angiopathy, and free radical production. Baik et al. [78] used live two-photon microscopy in vivo imaging and flow cytometry to confirm that the activated microglia surrounding Aβ plaques can phagocytose the plaques and die afterward. The accumulated Aβ is then released into the extracellular space by these dying microglia, which contributes to the growth of Aβ plaques. Cerebral amyloid angiopathy (CAA) is the most common AD complication, which is mainly manifested by the β-amyloid deposition in cerebrovascular walls. Moreover, Meyer-Luehmann et al. [79] developed a novel in vivo multiphoton imaging method and observed Aβ plaques and amyloid angiopathy by methoxy-X04 and thS, which was consistent with previous results obtained by Bacskai et al. Furthermore, Domnitz et al. [80] performed two-photon fluorescence imaging of the brain using a Ti:Sapphire laser at the 750 nm excitation wavelength, compared four different AD mouse models, and showed that Aβ accumulation in cerebral arteries begins as early as 9 months in Tg2576 mice. In addition, PS1xTg2576 and TgCRND8 mice also showed all superficial vessels affected by the end stage of disease, whereas aged PDAPP mice developed significant but not such extensive CAA. Additionally, Maria et al. [81] found that HS-84 and HS-169 were able to image Aβ aggregates and CAA by MPEF in the APP/PS1 mouse both in vivo and in vitro.
Since the near-infrared light used for multiphoton imaging does not oxidize the fluorogenic free radical indicators even after prolonged exposure, McLellan et al. [82] utilized the fluorogenic free radical indicator to mark Aβ plaques. Consequently, it turned out that the indicator was only associated with dense core Aβ plaques rather than diffuse plaques. In addition, the antioxidant therapy neutralizes these highly reactive molecules and may therefore be of therapeutic value in AD.
Hefendehl et al. reported using TPEF to study the formation of amyloid plaques in vivo in the brains of APP/PS1 transgenic mice over 6 months to evaluate the progression of amyloid plaques in vivo in the AD animal model [83]. A novel head fixation system was designed by this research group to provide stable and effective long-term tracking of individual plaques over time [83,84]. This head immobilization method allows for speedy relocation of previous imaged regions of interest (ROIs) inside the brain. This kind of ROIs can be automatically relocated and imaged from weeks to months with trivial rotational changes and only a few translational errors [84].
In addition to using a variety of fluorescent probes to detect Aβ, Kwan et al. [85] found the self-fluorescence of Aβ plaques and collagen in the tissue of AD mouse by MPEF and SHG images. Moreover, Wang et al. [86] successfully imaged the intracellular and extracellular Aβ deposition in the APP/PS1 mouse by label-free MPEF, which can prevent the cells from being damaged by some toxic fluorescent substances, providing the basis for advancing the use of label-free MPEF technology.

5.2. Second- and Third-Harmonic Generation Microscopy

SHG [87,88] and THG [89,90,91] microscopy imaging technologies have rapidly been developed in recent years. Second- and THG processes are different from multiphoton fluorescence excitation, and the harmonic wavelength generated is exactly equal to a half and one-third of the excitation wavelength. Moreover, no energy absorption was noted in the imaging process. Thus, damage to the sample could not be caused.
Despite the recent discovery that amyloid aggregates show increased multiphoton absorption properties, which are directly linked to fibrillization, most studies of amyloid structures were dependent on external probes [92,93,94] and only a few were label-free. The method to label-free image amyloid accumulates with MPEF microscopy had been proved very recently with an additional message obtained in the SHG imaging due to a high SHG susceptibility of the ordered fibrillar regions [43,92,94].
SHG and THG microscopies do not require sample labeling with exogenous probes, which could eliminate related toxic effects. These characteristics make the SHG an ideal tool for related applications, especially imaging of living cells and becoming a noninvasive imaging method [95,96]. However, SHG requires a noncentrosymmetric molecular structure, and only a very ordered structure can provide a sufficient SHG section. The SHG signal is not limited by the forward emission nature and can be collected backward. Thus, further development of SHG imaging is mainly reflected in the use of the combination with other optical imaging technologies. Moreover, SHG and TPEF are both nonlinear optical phenomena, which have many similarities, and are two completely different physical phenomena. The information obtained from the two phenomena can be compared with each other to confirm and supplement each other.
Kwan et al. [85] observed that the SHG signal of senile plaques in the hippocampus and brain vessels of transgenic AD mice corresponds with spontaneous fluorescence and ThS signals. Johansson et al. [94] used CLSM, MPEF, and SHG microscopy to perform label-free imaging of the amyloid plaques. Consequently, the subsequent two techniques have a high image contrast.
THG is a high harmonic technology developed after the second harmonic. The third harmonic is a third-order nonlinear effect, and the signal intensity is proportional to the third power of the excitation light. The second harmonic can only be generated in noncentrosymmetric materials, while the third harmonic does not have this requirement, which makes up for this defect in principle. By using a light source of 1263 nm, Chakraborty et al. [97] were able to see label-free Aβ in transgenic mouse brain slices with THG microscopy, consistent with the immunohistochemical results. The study provides a foundation for deep high-resolution THG imaging of brain Aβ in living mice. Furthermore, Chakraborty et al. had distinguished Aβ plaques, NFTs, and axons in brain sections [98] by comparing the additive-color multi-harmonic generation microscopy images in the cortex, striatum, and hippocampus of mice, which further advanced the application potential of unlabeled imaging in animal studies in vivo and in vitro.

5.3. Coherent Raman Scattering Microscopy

Raman spectroscopy, as a characterization method, is widely used in materials, physics, chemistry, biology, and other fields in recent years [99,100,101]. However, Raman scattering (RS) is very weak, and especially spontaneous RS. Its intensity is 8 to 10 orders of magnitude lower than that of fluorescence, which requires a much longer acquisition time, making RS imaging difficult to apply in biomedical research. Coherent RS (CRS) is a new microscopy imaging technology, which provides imaging contrast by detecting the characteristic vibration of the target molecule, and greatly enhances the RS signal based on nonlinear optical process, and improves the imaging rate and detection sensitivity. This section discusses the application of CRS in Aβ plaque imaging. Moreover, CRS microscopy mainly includes CARS [90,102,103,104] and SRS [105,106].
CARS imaging was introduced in 1999 by Xie’s group in the Pacific Northwest National Laboratory [104]. In 2008, the same group reported SRS [107]. Both CARS and SRS are third-order nonlinear optical processes in which the pump and Stokes light are used as excitation light. This means that these two processes happen simultaneously, but they are not generated and detected in the same way. Compared with CARS, the biggest advantage of SRS imaging is that no non-resonant background was noted, and its spectral profile is completely consistent with the spontaneous Raman spectrum.
CARS, which is nonlinear RS with anti-Stokes wave detection, provides an advanced noninvasive and label-free technique capable of selective imaging of major types of macromolecules (i.e., proteins, lipids, nucleic acids, and saccharides) [107]. Moreover, CARS imaging allows for label-free visualization of lipids at their characteristic frequency (2840 cm−1) [108,109,110], providing a tool to monitor lipid metabolism in live neuronal cells in real-time. CARS has a good lipid aggregation characterization, which is an important process that leads to Aβ aggregation. Observing the changes of lipids and Aβ is an important means to study AD. Using CARS microscopy, Kiskis et al. [44] have shown that a subpopulation of fibrillar Aβ plaques co-localizes with lipid deposits, and no lipid deposits were noted in diffuse plaques. Moreover, the lipid fluidity varies throughout the plaque region, which determines to what extent toxic Aβ oligomers could be released from the fibrillar plaques. This allows further investigation of the complex interactions between lipids and Aβ and deepens the understanding of the mechanisms of Aβ plaque toxicity.
Enejder et al. [111] found that two-photon FM of ThS staining did not provide a complete picture of the spatial distribution or molecular composition of Aβ plaques, which can be provided by CARS, promoting the extensive application of CARS microscopy in the field of AD research. Lee et al. [43] compared the microscopic images of CARS, TPEF, and SHG in normal AD mice. The result proved that the amount of lipids, Aβ, and collagens is greater in AD samples than in normal samples.
In addition to selectively imaging ordinary molecules based on their spectral differences, SRS can also see conformational changes in proteins. The formation of senile plaques is usually due to the accumulation of misfolded polypeptides which are the secondary structural changes of proteins from the α helix misfolded to β-sheet transitions. Moreover, the amide I band is highly sensitive to this kind of structural change. Ji et al. [112] applied the blue-shifted amide I band that happened in the forming of senile plaques to observe misfolded Aβ plaques in AD brain tissues via label-free multicolor SRS imaging.

6. Summary and Outlook

Optical imaging can achieve both labeled and unlabeled imaging. Moreover, the former has good specificity and the latter is suitable for living organisms. The development of optical imaging has experienced a process from qualitative to quantitative, two-dimensional to three-dimensional, in vitro to in vivo imaging. Based on the advantages of noninvasiveness, small biological damage, high sensitivity, low cost, fast imaging speed, and three-dimensional imaging, optical imaging has been widely used in the detection of biological processes at the cellular or molecular level. Since AD cannot be detected at an early stage and cannot be effectively cured, early detection of Aβ has very important research significance and application value for the treatment and prevention of AD. This review briefly introduced the principles of commonly used optical imaging methods and their applications in Aβ plaque imaging. To provide a reference in this field, this review summarized the various optical imaging methods that have been used in the current Aβ study as shown in Table 1, and the characteristics of these optical imaging methods are summarized in Table 2.
Optical imaging has demonstrated promising results in the study of Aβ plaques. However, some problems that need to be resolved still exist before their clinical application. Introducing multimodal nonlinear optical imaging into biomedical research can overcome this limitation because every nonlinear optical microscopy imaging modality is only sensitive to specific molecules or structures. Moreover, Gualda et al. [113] used the combination of CARS and TPEF to study the interaction between peptides and lipid bilayers. Using a multimodal multiphoton system, Lee et al. [43] obtained and compared the CARS, TPEF, and SHG microscopy images of CA-1 and DG regions of normal and AD mice, showing that the multimodal microscopy images can reveal distinct molecular structures and components (lipids, amyloid-beta fiber, and collagen) of brain tissue associated with AD. New active focusing techniques are introduced, involving fiber optics and endoscopes, to improve the optical imaging depth. Choi et al. [114] developed a reflective matrix microscope that allowed them to perform microscopy mapping of neural networks in the brain tissue through the intact mouse skull, without spatial resolution loss. In terms of overcoming spatial resolution, better imaging quality can be obtained by increasing the aperture of the system and adopting a shorter working wavelength. In the aspect of improving the detection sensitivity, it may be an effective solution to reduce and eliminate the noise from the modulation of the light source and the data acquisition design. Moreover, the ghost imaging method can be used to accelerate the imaging speed of a super-resolution fluorescent optical microscope, which is expected to capture the biological processes occurring in cells at a submillisecond speed. Thus, optical imaging technology can be predicted to have more progress in AD application with the unremitting efforts of researchers.

Author Contributions

Conceptualization, Z.L.; writing—original draft preparation, Z.L., H.X., L.L., T.Y.O., and J.Q.; writing—review and editing, Z.L., H.X., L.L., T.Y.O., and J.Q.; investigation, validation, and funding acquisition, J.Q. All authors have read and agreed to the published version of the manuscript.

Funding

This work has been partially supported by the National Natural Science Foundation of China (61835009/61620106016), Shenzhen Basic Research Project (JCYJ20170412105003520) and Shenzhen International Cooperation Project (GJHZ20180928161811821, GJHZ20190822095420249).

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Selkoe, D.J. Alzheimer’s Disease: Genes, Proteins, and Therapy. Phys. Rev. 2001, 81, 741–766. [Google Scholar] [CrossRef] [PubMed]
  2. Bolduc, D.M.; Montagna, D.R.; Seghers, M.C.; Wolfe, M.S.; Selkoe, D.J. The amyloid-beta forming tripeptide cleavage mechanism of gamma-secretase. eLife 2016, 5. [Google Scholar] [CrossRef]
  3. Bushman, D.M.; Kaeser, G.E.; Siddoway, B.; Westra, J.W.; Rivera, R.R.; Rehen, S.K.; Yung, Y.C.; Chun, J. Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer’s disease brains. eLlife 2015, 4, e05116. [Google Scholar] [CrossRef] [PubMed]
  4. de Wilde, M.C.; Overk, C.R.; Sijben, J.W.; Masliah, E. Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement. 2016, 12, 633–644. [Google Scholar] [CrossRef] [Green Version]
  5. Patterson, C. World Alzheimer Report 2018; Alzheimer’s Disease International (ADI): London, UK, 2018. [Google Scholar]
  6. Kelly, L.; Seifi, M.; Ma, R.; Mitchell, S.J.; Rudolph, U.; Viola, K.L.; Klein, W.L.; Lambert, J.J.; Swinny, J.D. Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer’s patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathol. Appl. Neurobiol. 2020, 47, 488–505. [Google Scholar] [CrossRef] [PubMed]
  7. Alberdi, E.; Sanchez-Gomez, M.V.; Cavaliere, F.; Perez-Samartin, A.; Zugaza, J.L.; Trullas, R.; Domercq, M.; Matute, C. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010, 47, 264–272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Luo, X.; Weber, G.A.; Zheng, J.; Gendelman, H.E.; Ikezu, T. C1q–calreticulin induced oxidative neurotoxicity: Relevance for the neuropathogenesis of Alzheimer’s disease. J. Neuroimmunol. 2003, 135, 62–71. [Google Scholar] [CrossRef]
  9. Murakami, K.; Shimizu, T.; Irie, K. Formation of the 42-mer Amyloid beta Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer’s Disease. J. Amino. Acids. 2011, 2011, 654207. [Google Scholar] [CrossRef] [Green Version]
  10. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356. [Google Scholar] [CrossRef] [Green Version]
  11. Bruggink, K.A.; Jongbloed, W.; Biemans, E.A.; Veerhuis, R.; Claassen, J.A.; Kuiperij, H.B.; Verbeek, M.M. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal. Biochem. 2013, 433, 112–120. [Google Scholar] [CrossRef]
  12. Damian, A.D.L.F.A.; Castellano, G.; Savio, E.; Buccino, P.; Aguiar, B.; Quagliata, A.; Cano, F.; Gonzalez, M.; Dansilio, S.; Kmaid, A. Resveratrol in Alzheimer’s disease: A PIB positron emission tomography/computed tomography study. Eur. J. Nucl. Med. Mol. Imaging. 2015, 42, S135. [Google Scholar]
  13. Yao, Z.; Zhang, Y.; Lin, L.; Zhou, Y.; Xu, C.; Jiang, T.; Alzheimer’s Disease Neuroimaging Initiative. Abnormal cortical networks in mild cognitive impairment and Alzheimer’s disease. PLoS Comput. Biol. 2010, 6, e1001006. [Google Scholar] [CrossRef]
  14. Zhu, X.; Smith, M.A.; Honda, K.; Aliev, G.; Moreira, P.I.; Nunomura, A.; Casadesus, G.; Harris, P.L.; Siedlak, S.L.; Perry, G. Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci. 2007, 257, 240–246. [Google Scholar] [CrossRef] [Green Version]
  15. He, Y. Advances in neuroimaging studies of Alzheimer’s disease. Prog. Biochem. Biophys. 2012, 39, 811–815. [Google Scholar] [CrossRef]
  16. Caroli, A.; Testa, C.; Geroldi, C.; Nobili, F.; Barnden, L.R.; Guerra, U.P.; Bonetti, M.; Frisoni, G.B. Cerebral perfusion correlates of conversion to Alzheimer’s disease in amnestic mild cognitive impairment. J. Neurol. 2007, 254, 1698–1707. [Google Scholar] [CrossRef]
  17. Ortiz, A.; Górriz, J.M.; Ramírez, J.; Martínez-Murcia, F.J. LVQ-SVM based CAD tool applied to structural MRI for the diagnosis of the Alzheimer’s disease. Pattern Recognit. Lett. 2013, 34, 1725–1733. [Google Scholar] [CrossRef]
  18. Pennanen, C.; Kivipelto, M.; Tuomainen, S.; Hartikainen, P.; Hänninen, T.; Laakso, M.P.; Hallikainen, M.; Vanhanen, M.; Nissinen, A.; Helkala, E.-L.; et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol. Aging. 2004, 25, 303–310. [Google Scholar] [CrossRef]
  19. Johnson, S.C.; Saykin, A.J.; Baxter, L.C.; Flashman, L.A.; Santulli, R.B.; McAllister, T.W.; Mamourian, A.C. The relationship between fMRI activation and cerebral atrophy: Comparison of normal aging and alzheimer disease. NeuroImage 2000, 11, 179–187. [Google Scholar] [CrossRef]
  20. Koepp, M.J.; Woermann, F.G. Imaging structure and function in refractory focal epilepsy. Lancet Neurol. 2005, 4, 42–53. [Google Scholar] [CrossRef]
  21. Gustavsson, T.; Syvanen, S.; O’Callaghan, P.; Sehlin, D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer’s disease. Transl. Neurodegener. 2020, 9, 37. [Google Scholar] [CrossRef] [PubMed]
  22. Song, I.U.; Im, J.J.; Jeong, H.; Na, S.H.; Chung, Y.A. Possible neuroprotective effects of rasagiline in Alzheimer’s disease: A SPECT study. Acta Radiol. 2020, 6, 784–790. [Google Scholar] [CrossRef]
  23. Zeng, H.M.; Han, H.B.; Zhang, Q.F.; Bai, H. Application of modern neuroimaging technology in the diagnosis and study of Alzheimer’s disease. Neural Regen. Res. 2021, 16, 73–79. [Google Scholar] [CrossRef] [PubMed]
  24. Nesterov, E.E.; Skoch, J.; Hyman, B.T.; Klunk, W.E.; Bacskai, B.J.; Swager, T.M. In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. Angew. Chem. 2005, 117, 5588–5592. [Google Scholar] [CrossRef]
  25. Raymond, S.B.; Skoch, J.; Hills, I.D.; Nesterov, E.E.; Swager, T.M.; Bacskai, B.J. Smart optical probes for near-infrared fluorescence imaging of Alzheimer’s disease pathology. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35 (Suppl. S1), S93–S98. [Google Scholar] [CrossRef]
  26. Skoch, J.; Dunn, A.; Hyman, B.T.; Bacskai, B.J. Development of an optical approach for noninvasive imaging of Alzheimer’s disease pathology. J. Biomed. Opt. 2005, 10, 11007. [Google Scholar] [CrossRef] [PubMed]
  27. Jarvet, J.; Gräslund, A.; Tiiman, A.; Vukoevic, V. Monitoring of Alzheimer’s Amyloid-β Peptide Aggregation via Fluorescence Correlation Spectroscopy and Total Internal Reflection Microscopy. Biophys. J. 2018, 114, 222a–223a. [Google Scholar] [CrossRef]
  28. Navarro, A.; del Valle, E.; Martinez, E.; Ordonez, C.; Perez, C.; Tolivia, J. Highly selective and fast diagnosis of Alzheimer’s disease hallmark lesions using Congo Red in isopropyl alcoholic solution. J. Alzheimers Dis. 2013, 35, 589–597. [Google Scholar] [CrossRef] [PubMed]
  29. Rembe, C.; Dräbenstedt, A. Laser-scanning confocal vibrometer microscope: Theory and experiments. Rev. Sci. Instrum. 2006, 77, 083702. [Google Scholar] [CrossRef]
  30. Wu, J.S.; Chung, Y.C.; Chien, J.J.; Chou, C. Improved axial point spread function in a two-frequency laser scanning confocal fluorescence microscope. J. Biomed. Opt. 2018, 23, 1–4. [Google Scholar] [CrossRef]
  31. Zhang, Y.; Leng, J.; Hu, W. A multiscale study on photophysical properties of a novel fluorescent probe for imaging amyloid-β in Alzheimer’s disease. Int. J. Quantum Chem. 2020, 120, e26344. [Google Scholar] [CrossRef]
  32. Yang, J.; Yang, J.; Li, Y.; Xu, Y.; Ran, C. Near-infrared Fluorescence Ocular Imaging (NIRFOI) of Alzheimer’s Disease. Mol. Imaging Biol. 2019, 21, 35–43. [Google Scholar] [CrossRef]
  33. Cheng, X.R.; Sze Hung, V.W.; Scarano, S.; Mascini, M.; Minunni, M.; Kerman, K. Label-free methods for probing the interaction of clioquinol with amyloid-β. Anal. Methods. 2012, 4, 2228–2232. [Google Scholar] [CrossRef]
  34. Geng, J.; Qu, K.; Ren, J.; Qu, X. Rapid and efficient screening of Alzheimer’s disease beta-amyloid inhibitors using label-free gold nanoparticles. Mol. Biosyst. 2010, 6, 2389–2391. [Google Scholar] [CrossRef]
  35. Chen, L.-W.; Zhou, Y.; Wu, M.-X.; Hong, M.-H. Remote-mode microsphere nano-imaging: New boundaries for optical microscopes. Opto-Electron. Adv. 2018, 1, 17000101. [Google Scholar] [CrossRef] [Green Version]
  36. Horneber, A.; Braun, K.; Rogalski, J.; Leiderer, P.; Meixner, A.J.; Zhang, D. Nonlinear optical imaging of single plasmonic nanoparticles with 30 nm resolution. Phys. Chem. Chem. Phys. 2015, 17, 21288–21293. [Google Scholar] [CrossRef] [Green Version]
  37. Le, T.T.; Langohr, I.M.; Locker, M.J.; Sturek, M.; Cheng, J.X. Label-free molecular imaging of atherosclerotic lesions using multimodal nonlinear optical microscopy. J. Biomed. Opt. 2007, 12, 054007. [Google Scholar] [CrossRef] [Green Version]
  38. Li, L.; Jiang, L.; Chen, Z.; Kang, D.; Yang, Z.; Liu, X.; Jiang, W.; Zhuo, S.; Guan, G.; Zhou, Y.; et al. Nonlinear optical microscopy for label-free detection of gastrointestinal neuroendocrine tumors. Lasers Med. Sci. 2016, 31, 1285–1291. [Google Scholar] [CrossRef]
  39. Schlickriede, C.; Waterman, N.; Reineke, B.; Georgi, P.; Li, G.; Zhang, S.; Zentgraf, T. Imaging through Nonlinear Metalens Using Second Harmonic Generation. Adv. Mater. 2018, 30, 1703843. [Google Scholar] [CrossRef] [Green Version]
  40. Yazdanfar, S.; Chen, Y.Y.; So, P.T.; Laiho, L.H. Multifunctional imaging of endogenous contrast by simultaneous nonlinear and optical coherence microscopy of thick tissues. Microsc. Res. Tech. 2007, 70, 628–633. [Google Scholar] [CrossRef]
  41. Kachynski, A.V.P.A.; Kuzmin, A.N.; Ohulchanskyy, T.Y.; Baev, A.; Qu, J.; Prasad, P.N. Photodynamic therapy by in situ nonlinear photon conversion. Nat. Photonics 2014, 8, 455–461. [Google Scholar] [CrossRef]
  42. Zhang, S.; Liu, L.; Ren, S.; Li, Z.; Zhao, Y.; Yang, Z.; Hu, R.; Qu, J. Recent advances in nonlinear optics for bio-imaging applications. Opto-Electron. Adv. 2020, 3, 200003. [Google Scholar] [CrossRef]
  43. Lee, J.H.; Kim, D.H.; Song, W.K.; Oh, M.K.; Ko, D.K. Label-free imaging and quantitative chemical analysis of Alzheimer’s disease brain samples with multimodal multiphoton nonlinear optical microspectroscopy. J. Biomed. Opt. 2015, 20, 56013. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Kiskis, J.; Fink, H.; Nyberg, L.; Thyr, J.; Li, J.Y.; Enejder, A. Plaque-associated lipids in Alzheimer’s diseased brain tissue visualized by nonlinear microscopy. Sci. Rep. 2015, 5, 13489. [Google Scholar] [CrossRef] [Green Version]
  45. Koronyo-Hamaoui, M.; Koronyo, Y.; Ljubimov, A.V.; Miller, C.A.; Ko, M.K.; Black, K.L.; Schwartz, M.; Farkas, D.L. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage 2011, 54 (Suppl. S1), S204–S217. [Google Scholar] [CrossRef] [Green Version]
  46. Ziv, Y.; Avidan, H.; Pluchino, S.; Martino, G.; Schwartz, M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc. Natl. Acad. Sci. USA 2006, 103, 13174–13179. [Google Scholar] [CrossRef] [Green Version]
  47. Frost, S.; Kanagasingam, Y.; Sohrabi, H.; Vignarajan, J.; Bourgeat, P.; Salvado, O.; Villemagne, V.; Rowe, C.C.; Macaulay, S.L.; Szoeke, C.; et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl. Psychiatry. 2013, 3, e233. [Google Scholar] [CrossRef]
  48. Tes, D.; Kratkiewicz, K.; Aber, A.; Horton, L.; Zafar, M.; Arafat, N.; Fatima, A.; Avanaki, M.R. Development and Optimization of a Fluorescent Imaging System to Detect Amyloid-beta Proteins: Phantom Study. Biomed. Eng. Comput. Biol. 2018, 9, 1179597218781081. [Google Scholar] [CrossRef] [Green Version]
  49. Ikonomovic, M.D.; Buckley, C.J.; Abrahamson, E.E.; Kofler, J.K.; Mathis, C.A.; Klunk, W.E.; Farrar, G. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-beta plaques in Alzheimer’s disease. Acta Neuropathol. 2020, 140, 463–476. [Google Scholar] [CrossRef]
  50. Hovis, D.B.; Heuer, A.H. The use of laser scanning confocal microscopy (LSCM) in materials science. J. Microsc. 2010, 240, 173–180. [Google Scholar] [CrossRef]
  51. Ya-li, L. Investigation and comparison of the endocytosis, transport and degradation mechanisms of β-amyloid monomers and oligomers in astrocytes. Ph.D. Thesis, Huazhong University of Science and Technology, Wuhan, China, 2013. [Google Scholar]
  52. Icke, I.; Zhang, A.Z.; Singh, S.; Dogdas, B.; Mirescu, C.; Kennedy, M.; Bardehle, S.; Tomaszewski, J.E.; Ward, A.D. 3D profiling of amyloid plaque-associated microglia and neuronal damage on confocal fluorescence images to aid drug discovery in Alzheimer’s disease. In Proceedings of the Medical Imaging 2019: Digital Pathology, San Diego, CA, USA, 16–21 February 2019. [Google Scholar]
  53. Zhang, R.; Zhou, T.; Liu, L.; Ohulchanskyy, T.Y.; Qu, J. Dose–effect relationships for PBM in the treatment of Alzheimer’s disease. J. Phys. D Appl. Phys. 2021, 54, 353001. [Google Scholar] [CrossRef]
  54. Iaccarino, H.F.; Singer, A.C.; Martorell, A.J.; Rudenko, A.; Gao, F.; Gillingham, T.Z.; Mathys, H.; Seo, J.; Kritskiy, O.; Abdurrob, F.; et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 2016, 540, 230–235. [Google Scholar] [CrossRef] [Green Version]
  55. Singer, A.C.; Martorell, A.J.; Douglas, J.M.; Abdurrob, F.; Attokaren, M.K.; Tipton, J.; Mathys, H.; Adaikkan, C.; Tsai, L.H. Noninvasive 40-Hz light flicker to recruit microglia and reduce amyloid beta load. Nat. Protoc. 2018, 13, 1850–1868. [Google Scholar] [CrossRef]
  56. Alsunusi, S.; Kumosani, T.A.; Glabe, C.G.; Huwait, E.A.; Moselhy, S.S. In vitro study of the mechanism of intraneuronal beta-amyloid aggregation in Alzheimer’s disease. Arch. Physiol. Biochem. 2020, 1–8. [Google Scholar] [CrossRef] [PubMed]
  57. Chibhabha, F.; Yang, Y.; Ying, K.; Jia, F.; Zhang, Q.; Ullah, S.; Liang, Z.; Xie, M.; Li, F. Non-invasive optical imaging of retinal Abeta plaques using curcumin loaded polymeric micelles in APPswe/PS1DeltaE9 transgenic mice for the diagnosis of Alzheimer’s disease. J. Mater. Chem. B 2020, 8, 7438–7452. [Google Scholar] [CrossRef] [PubMed]
  58. Wang, Y.-L.; Fan, C.; Xin, B.; Zhang, J.-P.; Luo, T.; Chen, Z.-Q.; Zhou, Q.-Y.; Yu, Q.; Li, X.-N.; Huang, Z.-L.; et al. AIE-based super-resolution imaging probes for β-amyloid plaques in mouse brains. Mater. Chem. Front. 2018, 2, 1554–1562. [Google Scholar] [CrossRef]
  59. Ni, R.; Chen, Z.; Gerez, J.; Shi, G.; Villois, A.; Zhou, Q.; Riek, R.; Nilsson, K.P.R.; Klohs, J.; Razansky, D. Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy. Biomed Opt Express. 2020, 11, 4989–5002. [Google Scholar] [CrossRef]
  60. Long, B.; Li, X.; Zhang, J.; Chen, S.; Li, W.; Zhong, Q.; Li, A.; Gong, H.; Luo, Q. Three-dimensional quantitative analysis of amyloid plaques in the whole brain with high voxel resolution. Sci. Sin. (Vitae) 2019, 49, 10. [Google Scholar] [CrossRef] [Green Version]
  61. Zhang, X.; Tian, Y.; Zhang, C.; Tian, X.; Ross, A.W.; Moir, R.D.; Sun, H.; Tanzi, R.E.; Moore, A.; Ran, C. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2015, 112, 9734–9739. [Google Scholar] [CrossRef] [Green Version]
  62. Chen, C.; Liang, Z.; Zhou, B.; Ip, N.; Qu, J.Y. Deep brain two-photon NIR fluorescence imaging for study of Alzheimer’s disease. Neural Imaging Sens. 2018. [Google Scholar] [CrossRef]
  63. Ralph-Weissleder, V.N. Shedding light onto live molecular targets. Nat. Med. 2003, 9, 123–128. [Google Scholar] [CrossRef]
  64. Ran, C.; Xu, X.; Raymond, S.B.; Ferrara, B.J.; Neal, K.; Bacskai, B.J.; Medarova, Z.; Moore, A. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. J. Am. Chem. Soc. 2009, 131, 15257–15261. [Google Scholar] [CrossRef] [Green Version]
  65. Raymond, S.B.; Kumar, A.T.; Boas, D.A.; Bacskai, B.J. Optimal parameters for near infrared fluorescence imaging of amyloid plaques in Alzheimer’s disease mouse models. Phys. Med. Biol. 2009, 54, 6201–6216. [Google Scholar] [CrossRef] [Green Version]
  66. Schmidt, A.; Pahnke, J. Efficient near-infrared in vivo imaging of amyoid-beta deposits in Alzheimer’s disease mouse models. J. Alzheimers Dis. 2012, 30, 651–664. [Google Scholar] [CrossRef] [Green Version]
  67. Helmchen, F.; Denk, W. Deep tissue two-photon microscopy. Nat. Methods 2005, 2, 932–940. [Google Scholar] [CrossRef]
  68. Miller, D.R.; Jarrett, J.W.; Hassan, A.M.; Dunn, A.K. Deep Tissue Imaging with Multiphoton Fluorescence Microscopy. Curr. Opin. Biomed. Eng. 2017, 4, 32–39. [Google Scholar] [CrossRef]
  69. Schenke-Layland, K.; Riemann, I.; Damour, O.; Stock, U.A.; Konig, K. Two-photon microscopes and in vivo multiphoton tomographs--powerful diagnostic tools for tissue engineering and drug delivery. Adv. Drug Deliv. Rev. 2006, 58, 878–896. [Google Scholar] [CrossRef]
  70. Dong, J.; Revilla-Sanchez, R.; Moss, S.; Haydon, P.G. Multiphoton in vivo imaging of amyloid in animal models of Alzheimer’s disease. Neuropharmacology 2010, 59, 268–275. [Google Scholar] [CrossRef] [Green Version]
  71. Christie, R.H.; Bacskai, B.J.; Zipfel, W.R.; Williams, R.M.; Hyman, B.T. Growth arrest of individual senile plaques in a model of Alzheimer’s disease observed by in vivo multiphoton microscopy. J. Neurosci. 2001, 21, 858–864. [Google Scholar] [CrossRef] [Green Version]
  72. Bacskai, B.J.; Hyman, B.T. Alzheimer’s disease: What multiphoton microscopy teaches us. Neuroscientist 2002, 8, 386–390. [Google Scholar] [CrossRef] [PubMed]
  73. Bacskai, B.J.; Skoch, J.; Hickey, G.A.; Allen, R.; Hyman, B.T. Fluorescence resonance energy transfer determinations using multiphoton fluorescence lifetime imaging microscopy to characterize amyloid-beta plaques. J. Biomed. Opt. 2003, 8, 368–375. [Google Scholar] [CrossRef]
  74. Brian, J.; Bacskai, S.T.K.; Kasischke, K.A.; Christie, R.H.; Webb, W.W.; Zipfel, W.R.; Williams, R.M.; Hyman, B.T. Chronic imaging of amyloid plaques in the live mouse brain using multiphoton microscopy. Proc. SPIE Int. Soc. Opt. Eng. 2001, 4262, 125–133. [Google Scholar]
  75. Bacskai, B.J.K.; Stephen, T.; Christie, R.H.; Cordelia, C.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 2001, 7, 369–372. [Google Scholar] [CrossRef]
  76. Chen, C.; Liang, Z.; Zhou, B.; Li, X.; Lui, C.; Ip, N.Y.; Qu, J.Y. In Vivo Near-Infrared Two-Photon Imaging of Amyloid Plaques in Deep Brain of Alzheimer’s Disease Mouse Model. ACS Chem. Neurosci. 2018, 9, 3128–3136. [Google Scholar] [CrossRef]
  77. Yan, P.; Bero, A.W.; Cirrito, J.R.; Xiao, Q.; Hu, X.; Wang, Y.; Gonzales, E.; Holtzman, D.M.; Lee, J.M. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci. 2009, 29, 10706–10714. [Google Scholar] [CrossRef] [Green Version]
  78. Baik, S.H.; Kang, S.; Son, S.M.; Mook-Jung, I. Microglia contributes to plaque growth by cell death due to uptake of amyloid beta in the brain of Alzheimer’s disease mouse model. Glia 2016, 64, 2274–2290. [Google Scholar] [CrossRef]
  79. Meyer-Luehmann, M.; Spires-Jones, T.L.; Prada, C.; Garcia-Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D.M.; Bacskai, B.J.; Hyman, B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 2008, 451, 720–724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Domnitz, S.B.; Robbins, E.M.; Hoang, A.W.; Alloza, M.G.; Hyman, B.T.; Rebeck, G.W.; Greenberg, S.M.; Bacskai, B.J.; Frosch, M.P. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2005, 64, 588–594. [Google Scholar] [CrossRef] [Green Version]
  81. Calvo-Rodriguez, M.; Hou, S.S.; Snyder, A.C.; Dujardin, S.; Shirani, H.; Nilsson, K.P.R.; Bacskai, B.J. In vivo detection of tau fibrils and amyloid beta aggregates with luminescent conjugated oligothiophenes and multiphoton microscopy. Acta Neuropathol. Commun. 2019, 7, 171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  82. Megan, E.; McLellan, S.T.K.; Bradley, T.; Hyman, B.; Bacskai, J. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 2003, 23, 2212–2217. [Google Scholar]
  83. Hefendehl, J.K.; Wegenast-Braun, B.M.; Liebig, C.; Eicke, D.; Milford, D.; Calhoun, M.E.; Kohsaka, S.; Eichner, M.; Jucker, M. Long-term in vivo imaging of beta-amyloid plaque appearance and growth in a mouse model of cerebral beta-amyloidosis. J. Neurosci. 2011, 31, 624–629. [Google Scholar] [CrossRef] [PubMed]
  84. Hefendehl, J.K.; Milford, D.; Eicke, D.; Wegenast-Braun, B.M.; Calhoun, M.E.; Grathwohl, S.A.; Jucker, M.; Liebig, C. Repeatable target localization for long-term in vivo imaging of mice with 2-photon microscopy. J. Neurosci. Methods 2012, 205, 357–363. [Google Scholar] [CrossRef]
  85. Kwan, A.C.; Duff, K.; Gouras, G.K.; Webb, W.W. Optical visualization of Alzheimer’s pathology via multiphoton-excited intrinsic fluorescence and second harmonic generation. Opt. Exp. 2009, 17, 3679–3689. [Google Scholar] [CrossRef] [PubMed]
  86. Wang, S.; Lin, B.; Lin, G.; Sun, C.; Lin, R.; Huang, J.; Tao, J.; Wang, X.; Wu, Y.; Chen, L.; et al. Label-free multiphoton imaging of beta-amyloid plaques in Alzheimer’s disease mouse models. Neurophotonics 2019, 6, 045008. [Google Scholar] [CrossRef]
  87. Hsieh, C.-L.; Grange, R.; Pu, Y.; Psaltis, D. Bioconjugation of barium titanate nanocrystals with immunoglobulin G antibody for second harmonic radiation imaging probes. Biomaterials 2010, 31, 2272–2277. [Google Scholar] [CrossRef] [Green Version]
  88. Zavelani-Rossi, M.; Celebrano, M.; Biagioni, P.; Polli, D.; Finazzi, M.; Duò, L.; Cerullo, G.; Labardi, M.; Allegrini, M.; Grand, J.; et al. Near-field second-harmonic generation in single gold nanoparticles. Appl. Phys. Lett. 2008, 92, 093119. [Google Scholar] [CrossRef]
  89. Lippitz, M.; van Dijk, M.A.; Orrit, M. Third-harmonic generation from single gold nanoparticles. Nano Lett. 2005, 5, 799–802. [Google Scholar] [CrossRef]
  90. Cheng, J.X.; Jia, Y.K.; Zheng, G.F.; Xie, X.S. Laser-scanning coherent anti-Stokes Raman scattering microscopy and applications to cell biology. Biophys. J. 2002, 83, 502–509. [Google Scholar] [CrossRef] [Green Version]
  91. Liu, T.-M.; Tai, S.-P.; Yu, C.-H.; Wen, Y.-C.; Chu, S.-W.; Chen, L.-J.; Prasad, M.R.; Lin, K.-J.; Sun, C.-K. Measuring plasmon-resonance enhanced third-harmonic χ(3) of Ag nanoparticles. Appl. Phys. Lett. 2006, 89, 043122. [Google Scholar] [CrossRef]
  92. Hanczyc, P.; Samoc, M.; Norden, B. Multiphoton absorption in amyloid protein fibres. Nat. Photonics. 2013, 7, 969–972. [Google Scholar] [CrossRef] [Green Version]
  93. Heo, C.H.K.; Kim, H.J.; Baik, S.H.; Song, H.; Kim, Y.S.; Lee, J.; Mook-jung, I.; Kim, H.M. A two-photon fluorescent probe for amyloid-β plaques in living mice. Chem. Commun. 2013, 49, 1303–1305. [Google Scholar] [CrossRef] [PubMed]
  94. Johansson, P.K.; Koelsch, P. Label-free imaging of amyloids using their intrinsic linear and nonlinear optical properties. Biomed Opt. Express. 2017, 8, 743–756. [Google Scholar] [CrossRef] [Green Version]
  95. Campagnola, P.J.; Loew, L.M. Second-harmonic imaging microscopy for visualizing biomolecular arrays in cells, tissues and organisms. Nat. Biotechnol. 2003, 21, 1356–1360. [Google Scholar] [CrossRef]
  96. Williams, R.M.; Zipfel, W.R.; Webb, W.W. Interpreting second-harmonic generation images of collagen I fibrils. Biophys. J. 2005, 88, 1377–1386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Chakraborty, S.; Wu, P.-C.; Chen, S.-T.; Chiu, M.-J.; Sun, C.-K.; Shaked, N.T.; Hayden, O. Assessment of neuropathology of Alzheimer’s disease brain with high-resolution, label-free multi-harmonic generation microscopy. In Proceedings of the Label-free Biomedical Imaging and Sensing (LBIS) 2020, Symposium on Label-Free Biomedical Imaging and Sensing (LBIS), San Francisco, CA, USA, 1–4 February 2020. [Google Scholar]
  98. Chakraborty, S.; Chen, S.T.; Hsiao, Y.T.; Chiu, M.J.; Sun, C.K. Additive-color multi-harmonic generation microscopy for simultaneous label-free differentiation of plaques, tangles, and neuronal axons. Biomed. Opt. Express. 2020, 11, 571–585. [Google Scholar] [CrossRef]
  99. Kiefer, W. Recent advances in linear and nonlinear Raman spectroscopy II. J. Raman Spectrosc. 2008, 39, 1710–1725. [Google Scholar] [CrossRef]
  100. Nafie, L.A. Recent advances in linear and non-linear Raman spectroscopy. Part XI. J. Raman Spectrosc. 2017, 48, 1692–1717. [Google Scholar] [CrossRef]
  101. Opilik, L.; Schmid, T.; Zenobi, R. Modern Raman imaging: Vibrational spectroscopy on the micrometer and nanometer scales. Annu. Rev. Anal. Chem. 2013, 6, 379–398. [Google Scholar] [CrossRef]
  102. Müller, M.S.J.M. Imaging the thermodynamic state of lipid membranes with multiplex CARS microscopy. J. Phys. Chem. B 2002, 106, 3715–3723. [Google Scholar] [CrossRef]
  103. Volkmer, A.; Cheng, J.-X.; Sunney Xie, X. Vibrational Imaging with High Sensitivity via Epidetected Coherent Anti-Stokes Raman Scattering Microscopy. Phys. Rev. Lett. 2001, 87. [Google Scholar] [CrossRef] [Green Version]
  104. Zumbusch, A.; Holtom, G.R.; Xie, X. Three-dimensional vibrational imaging by coherent anti-Stokes Raman scattering. Phys. Rev. Lett. 1999, 82, 4142–4145. [Google Scholar] [CrossRef] [Green Version]
  105. Hu, C.R.; Zhang, D.; Slipchenko, M.N.; Cheng, J.X.; Hu, B. Label-free real-time imaging of myelination in the Xenopus laevis tadpole by in vivo stimulated Raman scattering microscopy. J. Biomed. Opt. 2014, 19, 086005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Wang, M.C.; Min, W.; Freudiger, C.W.; Ruvkun, G.; Xie, X.S. RNAi screening for fat regulatory genes with SRS microscopy. Nat. Methods. 2011, 8, 135–138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Freudiger, C.W.; Min, W.; Saar, B.G.; Lu, S.; Holtom, G.R.; He, C.; Tsai, J.C.; Kang, J.X.; Xie, X.S. Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science 2008, 322, 1857–1861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Pliss, A.; Kuzmin, A.N.; Kachynski, A.V.; Prasad, P.N. Biophotonic probing of macromolecular transformations during apoptosis. Proc. Natl. Acad. Sci. USA 2010, 107, 12771–12776. [Google Scholar] [CrossRef] [Green Version]
  109. Lim, R.S.; Kratzer, A.; Barry, N.P.; Miyazaki-Anzai, S.; Miyazaki, M.; Mantulin, W.W.; Levi, M.; Potma, E.O.; Tromberg, B.J. Multimodal CARS microscopy determination of the impact of diet on macrophage infiltration and lipid accumulation on plaque formation in ApoE-deficient mice. J. Lipid Res. 2010, 51, 1729–1737. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Li, S.; Li, Y.; Yi, R.; Liu, L.; Qu, J. Coherent Anti-Stokes Raman Scattering Microscopy and Its Applications. Front. Phys. 2020, 8, 515. [Google Scholar] [CrossRef]
  111. Annika, E.; Kiskis, J.; Fink, H.; Nyberg, L.; Thyr, J.; Li, J. CARS microscopy of Alzheimer’s diseased brain tissue. In Proceedings of the Multiphoton Microscopy in the Biomedical Sciences XIV, San Francisco, CA, USA, 2–4 February 2014. [Google Scholar]
  112. Minbiao, J.; Zhang, L.; Freudiger, C.W.; Hou, S.S.; Lin, D.; Yang, X.; Bacskai, B.J.; Xie, X.S. Label-free imaging of amyloid plaques in Alzheimer’s disease with stimulated Raman scattering microscopy. Sci. Adv. 2018, 4, eaat7715. [Google Scholar]
  113. Gualda, E.J.; Voglis, G.F.G.; Mari, M.; Fotakis, C.; Tavernarakis, N. In vivo imaging of cellular structures in Caenorhabditis elegans by combined TPEF, SHG and THG microscopy. J. Microsc. 2008, 229, 141–150. [Google Scholar] [CrossRef] [PubMed]
  114. Yoon, S.; Lee, H.; Hong, J.H.; Lim, Y.-S.; Choi, W. Laser scanning reflection-matrix microscopy for aberration-free imaging through intact mouse skull. Nat. Commun. 2020, 11, 1–12. [Google Scholar] [CrossRef]
Figure 1. Optical imaging for Aβ plaque detection and visualization.
Figure 1. Optical imaging for Aβ plaque detection and visualization.
Biosensors 11 00255 g001
Figure 2. Principle scheme of fluorescence microscopy.
Figure 2. Principle scheme of fluorescence microscopy.
Biosensors 11 00255 g002
Figure 3. Physical photos of a Micron II rodent retinal imaging microscope.
Figure 3. Physical photos of a Micron II rodent retinal imaging microscope.
Biosensors 11 00255 g003
Figure 4. Principle scheme of confocal laser scanning microscopy.
Figure 4. Principle scheme of confocal laser scanning microscopy.
Biosensors 11 00255 g004
Figure 5. Conventional microscopy vs. confocal microscopy (reproduced with permission from the National Institute of Biological Sciences, Beijing).
Figure 5. Conventional microscopy vs. confocal microscopy (reproduced with permission from the National Institute of Biological Sciences, Beijing).
Biosensors 11 00255 g005
Table 1. Optical imaging in Aβ research.
Table 1. Optical imaging in Aβ research.
Optical Imaging MethodProbesParametersImaged SamplesReference
FMcurcuminλex = 550/25 nm
λem = 605/70 nm
Resolution: 0.25 μm
retina slices[45]
FMCy5,
CRANAD-2
λex = 649 nm, λex = 649 nm
λem = 675 nm, λem = 715 nm
Resolution: 5 μm
laser power: 5~50 mW
agar phantom[48]
FM
CLSM
PiB
flutemetamol
λex = 330~390 nm
λem = 390~450 nm
Resolution: 0.10 × 0.108 × 0.11 μm
brain slices[49]
FM super-resolution imagesPD-NA,
PD-NA-TEG
λex = 405 nm
λem = 500~546 nm
Resolution: sub-100 nm
laser power: 50 mW
brain slices[58]
LMI-FMHS-169λex = 532 nm
Resolution: 20 μm
In vivo brain[59]
fMOSTDANIR-8cResolution: 0.32 × 0.32 × 2 μmIn vitro brain[60]
CLSMThTλex = 450 nm
λem = 482 nm
oAβ42[51]
CLSMThS1024 × 1024 pixelbrain slices[52]
CLSM12F41024 × 1024 pixelbrain slices[55]
CLSMspecific monoclonal M78 pheochromocytoma[56]
CLSMcurcumin micelles
12F4
λex = 405 nm
λem = 525 nm
a laser beam (2 mW) at 514 nm for 6 min.
brain and retinal slices[57]
NIRFAOI987,
NIAD-11,
NIAD-16
λex = 650 nm, λem = 670 nm
λex = 545 nm, λem = 690 nm
λex = 470 nm, λem = 720 nm
brain slices[25,65]
NIRFCRANAD-2λex = 640 nm, λem = 805 nm
laser power: 10 mW/cm2
532 × 256 pixels
In vivo and in vitro brain[64]
NIRFTHK-265λex = 665 nm, λem = 725 nm
169 or 84 μm resolution
brain slices[66]
NIRFCRANAD-102λex = 605 nm, λem = 680 nmbrain slices[32]
MPEFThStwo-photon fluorescence
λex = 750 nm
λem = 380~480 nm
laser power after the objective: 10 mW, pulse 60–100 fs
Resolution: 1 μm
depth = 150 μm
In vivo brain[71]
MPEFmethoxy-X04two-photon fluorescence
λex = 750 nm
λem = 435~485 nm
depth = 200 μm
In vivo brain[77]
MPEFmethoxy-X04two-photon fluorescence
λex = 850 nm
λem = 460 nm
laser power < 35 mW
In vivo brain[78]
MPEFmethoxy-X04two-photon fluorescence
λex = 800 nm
λem = 380~480 nm
Resolution: 150 × 150 × 1 μm
In vivo brain[79]
MPEFThStwo-photon fluorescence
λex = 750 nm
λem = 380~480 nm
depth = 200 μm
Resolution: 615 × 615 μm
In vitro brain[80]
MPEFHS-84,
HS-169
λex = ~375 nm and ~535 nm (double excitation peaks),
λem = ~ 665 nm
resolution of 512 × 512 pixels
depth = ~200 μm
brain slices[81]
MPEFThStwo-photon fluorescence
λex = 750 or 800 nm
λem = 380~480 nm
depth = 200 μm
Resolution: 615 × 615 μm
In vivo brain[82]
MPEF, SHGLabel-freetwo-photon fluorescence
λex = 810 nm
SHG signals λem = 395~415 nm
TPEF signals λem = 430~690 nm
laser power: 5~10 mW
1024 × 1024 pixel
brain slices[85]
MPEF, SHGLabel-freeMPEF λex = 830 nm
SHG signals λem = 387 nm
TPEF signals λem = 400~550 nm
laser power: 25 mW
brain slices[86]
CLSM, MPEF, SHGLabel-freeCLSM λex = 405 nm, λem > 420 nm
MPEF λex = 910 nm
SHG signals λem = 420~460 nm
TPEF signals λem = 495~540 nm
laser power: 680 mW
pixel sizes < 200 nm
brain slices[94]
THGLabel-freeMPEF λex = 1262 nm, λem > 430 nm
laser power: 20 mW
1024 × 1024 pixels
brain slices[97,98]
CARSThS
Cy2
Stokes λex = 1064 nm
Pump λex = 817 nm
the CH2 stretch vibration: 2845 cm−1
ThS signal: short-pass filters (600SP and 2 × 750SP, Ealing)
Cy2 signal: band-pass filter (525/50 nm, Chroma)
average laser power: 25 mW
brain slices[44,111]
SRSThSStokes λex = 1064 nm
Pump λex = 720~990 nm
maximum brightness of the plaque images: 1670 cm−1
the CH2 stretch vibration at 2845 cm−1
resolution: ~8 cm−1
brain slices[112]
CARS
TPEF
SHG
Label-freeStokes λex = 1064 nm
Pump λex = 800 nm
CARS: HQ650/20 m, Chroma,
TPEF: FF01-550/88,
SHG: FF01-390/18, Semrock
resolution: ~5 cm−1
laser power1: 20 mW
laser power2: 3 mW
brain slices[43]
In vivo brain: the brain of a living Alzheimer’s mouse. In vitro brain: the intact, postmortem brain of Alzheimer’s mouse.
Table 2. Characteristics of optical imaging methods and their applications in biology.
Table 2. Characteristics of optical imaging methods and their applications in biology.
Optical Imaging MethodAdvantagesDisadvantageApplications in Biology
FMEasy to operate, low costLow resolution and low contrastThin biological samples, slice
CLSMHigh resolution, high contrastExpensive, damage to living cells, time-consumingThick biological samples
NIRFFast imaging speed, high penetration, non-destructive,Poor sensitivity, vulnerable to interferenceIn vivo imaging
MPEFHigh penetration depth, low phototoxicityHigh cost,
complex system
In vivo imaging
SHGNo photobleaching, label-freeThe signal is weak and difficult to collectOccurs only in an asymmetric medium (e.g., collagen)
THGNo photobleaching, label-freeThe signal is weak and difficult to collectCan occur in any medium (whether symmetric or not)
CARSGood chemical specificity, small light damage, high sensitivity, high spatial resolution, fast scanning speedStrong non-resonant backgroundIn vivo imaging
SRSLow background noise, fast scanning speedExpensive, complex systemIn vivo imaging
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Luo, Z.; Xu, H.; Liu, L.; Ohulchanskyy, T.Y.; Qu, J. Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease. Biosensors 2021, 11, 255. https://doi.org/10.3390/bios11080255

AMA Style

Luo Z, Xu H, Liu L, Ohulchanskyy TY, Qu J. Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease. Biosensors. 2021; 11(8):255. https://doi.org/10.3390/bios11080255

Chicago/Turabian Style

Luo, Ziyi, Hao Xu, Liwei Liu, Tymish Y. Ohulchanskyy, and Junle Qu. 2021. "Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease" Biosensors 11, no. 8: 255. https://doi.org/10.3390/bios11080255

APA Style

Luo, Z., Xu, H., Liu, L., Ohulchanskyy, T. Y., & Qu, J. (2021). Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease. Biosensors, 11(8), 255. https://doi.org/10.3390/bios11080255

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop